Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT ID: NCT04447573

Last Updated: 2020-09-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-06-30
• Study Completion Date: 2022-12-30

Brief Summary

This study is aimed to evaluate the safety, feasibility and efficacy of BCMA CAR-T in the treatment of relapsed or refractory multiple myeloma

Detailed Description

This is a study to evaluate the safety, feasibility and efficacy of BCMA CAR-T in the treatment of relapsed or refractory multiple myeloma.

The Main research objectives:

To evaluate the safety and efficacy of BCMA CAR-T in patients with relapsed or refractory multiple myeloma

The Secondary research objectives:

To investigate the cytokinetic characteristics of BCMA CAR-T in patients with relapsed or refractory multiple myeloma.

Conditions

Multiple Myeloma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BCMA CAR-T cells

Patients will be treated with BCMA CAR-T cells

Group Type: EXPERIMENTAL

BCMA CAR-T

Intervention Type: BIOLOGICAL

Biological: BCMA CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;

Interventions

BCMA CAR-T

Biological: BCMA CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. The subjects voluntarily participated in the study and signed the informed consent form by themselves or their legal guardian;

2. According to the international standard for multiple myeloma (IMWG 2014);

3. Diagnosed as relapsed or refractory multiple myeloma. Relapsed and refractory were defined as follow. Relapsed: patients had received for at least 3 drugs with different mechanisms of action (including protease inhibitors and immunomodulators) and disease progression within 60 days of the most recent treatment. Refractory was defined as: disease progression occurred during the recent treatment, or disease progression occurred within 60 days after treatment;

4. The expression of BCMA in myeloma cells was reported as positive by flow cytometry or immunohistochemistry;

5. No antibody drug was administered within last 2 weeks before cell therapy;

6. ECOG Scores: 0~1

7. Echocardiography showed normal diastolic function, left ventricular ejection fraction (LVEF) ≥ 50%, no serious arrhythmia;

8. The subjects had no pulmonary infection, normal pulmonary function, and indoor air oxygen saturation ≥ 92%;

9. There was no contraindication for peripheral blood sampling;

10. The estimated survival time was more than 12 weeks;

11. The urine pregnancy test of female subjects of childbearing age should be negative and not in lactation; the female or male subjects of childbearing age should take effective contraceptive measures during the whole research process.

Exclusion Criteria

1. Have a history of allergy to any component of cell products;

2. There are clinically significant cardiovascular diseases, such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or any grade 3 (moderate) or grade 4 (severe) heart disease with cardiac function (according to the functional classification method of the New York Heart AssociationNYHA) with a history of myocardial infarction, angioplasty or stent implantation, unstable angina or other clinically significant heart disease within 12 months before admission;

3. who has suffered from brain injury, consciousness disorder, epilepsy, more serious cerebral ischemia or cerebral hemorrhage disease;

4. Patients who need urgent treatment due to tumor progression or spinal cord compression;

5. The investigator determines that there are serious complications or diseases that will increase the risk of the subject or affect the study, including but not limited to, for example, cirrhosis, recent major trauma, etc;

6. After allogeneic hematopoietic stem cell transplantation;

7. Patients with autoimmune diseases, immunodeficiency or other diseases requiring immunosuppressive （excluding glucocorticoid）therapy;

8. There was uncontrolled active infection;

9. There were live vaccinations within 4 weeks before admission;

10. Active hepatitis (positive for HBVDNA or HCVRNA), syphilis and other acquired and congenital immunodeficiency diseases, including but not limited to those with HIV infection;

11. Subjects had a history of alcohol, drug or mental illness;

12. The researchers believe that there are other conditions that subjects are not suitable to participate in this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Beijing Lu Daopei Hospital

OTHER

Sponsor Role: collaborator

Hebei Yanda Ludaopei Hospital

OTHER

Sponsor Role: collaborator

Hebei Senlang Biotechnology Inc., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Peihua Lu, PhD&MD

Role: PRINCIPAL_INVESTIGATOR

Beijing Lu Daopei Hospital

Locations

He bei Yan da Lu dao pei Hospital

Yanda, Hebei, China

Site Status: RECRUITING

BeiJing Ludaopei Hospital

Beijing, Yizhuang, China

Site Status: RECRUITING

Countries

China

Central Contacts

Peihua Lu, PhD&MD

Role: CONTACT

peihua_lu@126.com

008618611636172

Jianqiang Li, PhD&MD

Role: CONTACT

limmune@gmail.com

008615511369555

Facility Contacts

Peihua Lu, MD/PhD

Role: primary

Peihua Lu, PhD&MD

Role: primary

peihua_lu@126.com

008618611636172

References

Zhang XG, Wang L, Yang J, Hu XN, Wang H, Zhang LN, Zhou X, Liu Y, Wang Q, Lu PH. Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma. Blood Adv. 2025 Sep 23;9(18):4543-4552. doi: 10.1182/bloodadvances.2025016322.

Reference Type: DERIVED

PMID: 40569697 (View on PubMed)

Other Identifiers

BCMA CAR-T

Identifier Type: -

Identifier Source: org_study_id